Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms.
Neuroimmunomodulation. 2014-01-01; 21(2-3): 95-101
Lire sur PubMed
1. Neuroimmunomodulation. 2014;21(2-3):95-101. doi: 10.1159/000356535. Epub 2014 Feb
Chronic low-grade inflammation in metabolic disorders: relevance for behavioral
Lasselin J(1), Capuron L.
(1)Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, National
Institute of Agricultural Research (INRA) and Bordeaux University, Bordeaux,
The ability of cytokines to influence cerebral functions and to induce the
development of behavioral alterations is well established in conditions of acute
or chronic high-grade activation of the innate immune system. Recent evidence
suggests that the release of these immune mediators during chronic low-grade
endogenous inflammatory processes may also contribute to the development of
behavioral alterations. Metabolic disorders, including obesity, type 2 diabetes
and the metabolic syndrome, represent examples of those conditions which are both
characterized by a chronic low-grade inflammatory state and an increased
prevalence of behavioral disorders. In metabolic disorders, the increased
production of acute-phase proteins and cytokines (e.g. C-reactive protein,
interleukin-6 and tumor necrosis factor-α), but at relatively low levels, may
promote and contribute to the development of behavioral symptoms, including
depressive symptoms, cognitive impairment, fatigue, sleep problems and pain. This
hypothesis is supported by a growing literature referring both to experimental
and clinical findings that will be reviewed here.
© 2014 S. Karger AG, Basel.
PMID: 24557041 [Indexed for MEDLINE]